brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
DIMETANE-DX (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) is clinical pharmacology brompheniramine maleate is a histamine antagonist, specifically an h 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Approved for nasal congestion due to the common cold, hay fever, other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy and 2 more indications. First approved in 1984.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
DIMETANE-DX is a triple-combination oral syrup containing brompheniramine maleate (H1-receptor antagonist), dextromethorphan hydrobromide (antitussive), and pseudoephedrine hydrochloride (nasal decongestant). It treats nasal congestion, cough, and allergic symptoms associated with the common cold, hay fever, and upper respiratory allergies. The combination works through antihistamine, cough-suppression, and sympathomimetic mechanisms to address multiple cold and allergy symptoms simultaneously.
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling focus on market defense and potential transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Brompheniramine maleate is a histamine antagonist, specifically an H 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DIMETANE-DX offers limited growth trajectory due to LOE-approaching status and zero linked job openings, but provides valuable experience in defending established market positions and managing OTC portfolio complexity. Career progression would focus on operational excellence, trade management, and competitive positioning rather than expansion or innovation.